Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE).

Full DD Report for RARE

You must become a subscriber to view this report.


Recent News from (NASDAQ: RARE)

Ultragenyx Pharmaceutical, Inc. (RARE) CEO Emil Kakkis on Q3 2018 Results - Earnings Call Transcript
Ultragenyx Pharmaceutical, Inc. (RARE) Q3 2018 Earnings Conference Call November 5, 2018 17:00 ET Executives Danielle Keatley - IR Emil Kakkis - President, CEO & Director Shalini Sharp - EVP & CFO Analysts Gena Wang - Barclays Bank Cory Kasimov - JPMorgan Chase &a...
Source: SeekingAlpha
Date: November, 06 2018 06:58
Ultragenyx Pharmaceutical beats by $0.22, revenue in-line
Ultragenyx Pharmaceutical (NASDAQ: RARE ): Q3 GAAP EPS of -$1.74 beats by $0.22 . Revenue of $11.8M in-line. Press Release More news on: Ultragenyx Pharmaceutical Inc., Earnings news and commentary, Healthcare stocks news,
Source: SeekingAlpha
Date: November, 05 2018 16:09
Ultragenyx Reports Third Quarter 2018 Financial Results and Corporate Update
NOVATO, Calif., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today reported its financial results and corporate update for the quart...
Source: GlobeNewswire
Date: November, 05 2018 16:05
Notable earnings after Monday's close
ACHC , AEL , AKCA , ANDE , APLE , APTS , ATRO , ATUS , AVD , AWR , BE , BHF , BKD , BKH , BKNG , CAR , CBT , CDEV , COHU , CRZO , CTRE , CXW , DCO , DCP , DRH , DVAX , ELF , EVBG , FMC , FN , FNV , FRGI , FRPT , FTDR , HHC , IFF , INSY , IPAR , ITRI , ...
Source: SeekingAlpha
Date: November, 04 2018 17:35
Ultragenyx to Host Conference Call for Third Quarter 2018 Financial Results and Corporate Update
NOVATO, Calif., Oct. 30, 2018 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call on Monday, November...
Source: GlobeNewswire
Date: October, 30 2018 08:30
Ultragenyx Fails Trial, But Its Long-Term Track Can't Be Dismissed
Recently, Ultragenyx Pharmaceutical ( RARE ) announced that it had failed to meet the primary endpoint of a phase 3 study . This phase 3 study used a drug known as UX007 treating a rare genetic disorder known as Glucose Transporter Type 1 Deficiency Syndrome or Glut1DS. While the results ...
Source: SeekingAlpha
Date: October, 29 2018 13:02
Ultragenyx's DTX301 shows positive effect in OTC study
Ultragenyx Pharmaceuticals (NASDAQ: RARE ) announces positive results from its ongoing Phase 1/2 clinical trial evaluating gene therapy DTX301 in patients with a urea cycle disorder called ornithine transcarbamylase (OTC) deficiency. More news on: Ultragenyx Pharmaceutical Inc., Healthca...
Source: SeekingAlpha
Date: September, 27 2018 08:12
Ultragenyx Announces Positive Topline Cohort 2 Results from Phase 1/2 Clinical Study of DTX301 Gene Therapy in Ornithine Transcarbamylase (OTC) Deficiency and Progression to Higher Dose
Ureagenesis normalized in one patient in Cohort 2 Cohort 1 responder demonstrated continued biochemical improvement and clinical stability at Week 52 Higher-dose Cohort 3 patient enrollment to begin in 2018; data expected in mid-2019 NOVATO, Calif., Sept. 27, 2018 (GLOBE NEWSWI...
Source: GlobeNewswire
Date: September, 27 2018 07:00
Today's Research Reports on Trending Tickers: Agios Pharmaceuticals and Ultragenyx Pharmaceutical
NEW YORK, NY / ACCESSWIRE / September 6, 2018 / Major U.S. equities were mixed on Wednesday with tech stocks posting worst daily drop since July dragging Nasdaq lower. The Dow Jones Industrial Average was up 0.09 percent to close at 25,974.99, while the S&P 500 Index decreased 0.28 percen...
Source: ACCESSWIRE IA
Date: September, 06 2018 08:00
Gene therapy players under pressure
The Nasdaq's selloff notwithstanding, most gene therapy stocks are in the red. This morning, Sangamo Therapeutics ( SGMO -21.1% ) reported data on SB-913 that disappointed investors. More news on: Sangamo Therapeutics, Inc., AVROBIO, MeiraGTx Holdings plc, Healthcare stocks news, Stocks ...
Source: SeekingAlpha
Date: September, 05 2018 10:58

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-1484.3984.6985.4083.39175,639
2018-05-2165.7664.7966.4064.35775,161
2018-05-1864.4765.9366.0064.30372,466
2018-05-1764.7364.1865.0062.65530,550
2018-05-1662.6863.9465.0060.211,013,382

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1148,06263,76075.3795Short
2018-12-1065,85892,77770.9853Short
2018-12-0768,21394,30372.3339Short
2018-12-0635,86260,17559.5962Short
2018-12-0453,05381,67664.9554Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on RARE.


About Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE)

Logo for Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: RARE)

      Filing Type: CT ORDERFiling Source: edgar
      Filing Date: August, 30 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: August, 29 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: August, 22 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: August, 03 2018
      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: August, 03 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: August, 02 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: June, 21 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: June, 08 2018
      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 08 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 07 2018

       

       


      Daily Technical Chart for (NASDAQ: RARE)

      Daily Technical Chart for (NASDAQ: RARE)


      Stay tuned for daily updates and more on (NASDAQ: RARE)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: RARE)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in RARE is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of RARE and does not buy, sell, or trade any shares of RARE. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/